The trifunctional antibody ertumaxomab destroys tumor cells that express low levels of human epidermal growth factor receptor 2.
about
Bispecific antibodies for cancer therapy: the light at the end of the tunnel?Bispecific antibodies and their applicationsProtein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancerSelecting Targets for Tumor Imaging: An Overview of Cancer-Associated Membrane ProteinsCODV-Ig, a universal bispecific tetravalent and multifunctional immunoglobulin format for medical applications.The development of bispecific antibodies and their applications in tumor immune escape.Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodiesHave we overestimated the benefit of human(ized) antibodies?A FcγRIII-engaging bispecific antibody expands the range of HER2-expressing breast tumors eligible to antibody therapy.New Immunotherapy Strategies in Breast Cancer.Structural and functional characterization of the trifunctional antibody catumaxomabProtein conjugation with genetically encoded unnatural amino acids.Synthesis of bispecific antibodies using genetically encoded unnatural amino acids.Retargeting T cells for HER2-positive tumor killing by a bispecific Fv-Fc antibody.Mechanisms of Trastuzumab resistance in ErbB2-driven breast cancer and newer opportunities to overcome therapy resistance.Multiformat T-cell-engaging bispecific antibodies targeting human breast cancers.A Novel Bispecific Antibody against Human CD3 and Ephrin Receptor A10 for Breast Cancer Therapy.Trifunctional antibody ertumaxomab: Non-immunological effects on Her2 receptor activity and downstream signalingEfficient generation of stable bispecific IgG1 by controlled Fab-arm exchange.A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumorsSelf-assembled antibody multimers through peptide nucleic acid conjugation.HER2 as a target for breast cancer therapy.Cancer therapy with trifunctional antibodies: linking innate and adaptive immunity.Recent advances and future trends in the targeted therapy of metastatic gastric cancer.Immunotherapy for breast cancer: past, present, and future.Step-up/step-down perfusion approach for increased mAb 520C9 production by a hybridoma cell line.Efficient generation of bispecific IgG antibodies by split intein mediated protein trans-splicing system.Recent advances of bispecific antibodies in solid tumors.Ganglioside GD2-specific trifunctional surrogate antibody Surek demonstrates therapeutic activity in a mouse melanoma model.Development of optimal medium for production of commercially important monoclonal antibody 520C9 by hybridoma cell.World Bispecific Antibody Summit, September 27-28, 2011, Boston, MA.Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment.Harnessing the immune system in the battle against breast cancer.Bispecific antibodies in cancer immunotherapy.Metastatic and triple-negative breast cancer: challenges and treatment options
P2860
Q24644083-B1A459E4-6FC9-41D0-83A0-B3F4A933E929Q26774024-17630DBD-2AAD-40C7-8D19-DBDC092FF6C8Q26852215-A3089E14-E905-4850-8B1A-42F4A71F72A0Q28077999-97C40933-10BD-4A08-A868-855AAAEF03D8Q30360904-BF849FBF-1A17-4346-92A4-8762D337042DQ33630292-753E2DC9-B517-4DBF-8615-8495B512C776Q33895804-0AFC76E0-F1B1-4BD1-9D00-C8A496F0FDF6Q34142714-041AE18F-4118-48BD-BA26-334DB77A8262Q34221898-F72F6999-B99E-434F-BDC5-1AA906C44321Q34549227-8DAB89F0-BDCC-4665-9A4A-517F282E463CQ34619043-257B891C-004C-4C87-928A-F501FBD99FEDQ34838057-B52B15AF-F554-4B81-A170-37C2992B363BQ34986422-CB849E13-57A4-4F20-9E70-4C05FC0C20CAQ35005791-FD5C95D4-C62F-40B6-B304-C5CF3DEC02F1Q35624814-09C66B88-EE48-430D-8B13-AE5EFD065771Q35822172-C67DE6E1-E41F-4664-8C69-D02EF5EC24B1Q35871726-F0D70B27-0C50-4D22-8EAA-01F6E07556C1Q36402698-89B4A30B-CA80-4B4F-81BF-A6B218D5CE7CQ36729822-DE8F303A-7368-4B5B-9872-3DB590115CF3Q37076922-A4CE8CE5-36ED-45F6-9270-45115185D8FEQ37633102-91AC3133-607B-4FE7-B02F-42B4219D321EQ37705396-6B467DA8-E473-4BE3-854F-67858DFDA091Q37965555-95CDC138-3F09-4F51-905A-DB98A58C42DEQ38199128-898B5D8A-5D59-4FD2-98E0-FAF2AAE5334DQ38787696-9E6CD115-115F-4548-8011-0C59703C2684Q39255485-E65EBBE7-AE7B-4D3A-B740-E5CABB60CACCQ41489391-FEB73053-94EF-4900-B53C-02EB12DEBFD0Q41696278-7BEABA31-B4C1-4613-BB48-4E22176AC35AQ42053371-7E37DB90-CA35-40ED-8BC9-1C5683BB12EAQ43109224-3297FB82-EF0B-47A4-AA8F-745697E2AB31Q43155636-05EF604E-0D5A-4A5A-AC2C-CDD4083B0F02Q47103332-DCB2B1A5-9C50-4027-A8CA-BD696B573CF9Q49884762-DA54791D-BBAD-4FFE-8FB0-FA1C461A15CCQ51309023-913E94B4-7DD3-40A1-9B62-F8A7B44BAA2CQ57105258-41CE311E-135D-438E-B39B-C0AD7E217BB8
P2860
The trifunctional antibody ertumaxomab destroys tumor cells that express low levels of human epidermal growth factor receptor 2.
description
2009 nî lūn-bûn
@nan
2009 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
The trifunctional antibody ert ...... rmal growth factor receptor 2.
@ast
The trifunctional antibody ert ...... rmal growth factor receptor 2.
@en
The trifunctional antibody ert ...... rmal growth factor receptor 2.
@nl
type
label
The trifunctional antibody ert ...... rmal growth factor receptor 2.
@ast
The trifunctional antibody ert ...... rmal growth factor receptor 2.
@en
The trifunctional antibody ert ...... rmal growth factor receptor 2.
@nl
prefLabel
The trifunctional antibody ert ...... rmal growth factor receptor 2.
@ast
The trifunctional antibody ert ...... rmal growth factor receptor 2.
@en
The trifunctional antibody ert ...... rmal growth factor receptor 2.
@nl
P2093
P1433
P1476
The trifunctional antibody ert ...... rmal growth factor receptor 2.
@en
P2093
Alexandra Schoberth
Horst Lindhofer
Jürgen Hess
Michael Jäger
P304
P356
10.1158/0008-5472.CAN-08-2861
P407
P577
2009-05-12T00:00:00Z